α1-抗胰蛋白酶替代治疗的标准。
Criteria for alpha 1-antitrypsin substitution.
作者信息
Viskum K, Kok-Jensen A
机构信息
Department of Pulmonary Medicine P, Bispebjerg Hospital, Copenhagen, Denmark.
出版信息
Lung. 1990;168 Suppl:586-91. doi: 10.1007/BF02718181.
The pharmacology and safety of substitution treatment intravenously with alpha 1-antitrypsin (AAT) in patients deficient of AAT has been thoroughly investigated. The clinical efficacy of the treatment has so far not been established. The difficulties and uncertainties involved in defining the right persons for treatment, and determining the right time for a possible start of treatment are discussed. A controlled trail with participation of several European countries is suggested.
α1-抗胰蛋白酶（AAT）缺乏患者静脉替代治疗的药理学和安全性已得到充分研究。目前尚未确定该治疗的临床疗效。文中讨论了确定合适治疗对象以及确定可能开始治疗的合适时间所涉及的困难和不确定性。建议开展一项有几个欧洲国家参与的对照试验。
Zotero 插件